Company: GRCE
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001140361-25-030398
Chunk: 8

Company: Grace Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 8
Chunk 8
---
 investors in the 2025 Private Placement.

  14
  

 The 2025 Private Placement closed on February 11, 2025 (the “Closing Date”). The net proceeds to the Company were $13,705, after deducting fees and expenses.  
  
   Both 2025 Pre-funded Warrants and 2025 Common Warrants are presented under additional paid-in capital in the equity section of the unaudited condensed consolidated balance sheet as of June 30, 2025.
   
   During the three months ended June 30, 2025, 110,460 of the 2025 Pre-Funded Warrants were exercised for 110,456 shares of Common Stock.  
  
   2023 Private Placement
   In September 2023, the Company entered into a securities
purchase agreement (the “2023 Purchase Agreement”) with certain institutional
and accredited investors in connection with a private placement offering of the
Company’s securities (the “2023 Private Placement”). Pursuant to the 2023
Purchase Agreement, the Company offered and sold 1,951,371 Common Shares, at a
purchase price of $1.848 per Common Share and pre-funded warrants (“2023
Pre-Funded Warrants”) to purchase up to 2,106,853 Common Shares at a purchase
price equal to the purchase price per Common Share less $0.0001. Each 2023
Pre-Funded Warrant is exercisable for one Common Share at an exercise price of
$0.0001 per Common Share, is immediately exercisable, and will expire once
exercised in full. Pursuant to the 2023 Purchase Agreement, the Company also
issued, to such institutional and accredited investors, common warrants (the
“2023 Common Warrants” and, together with the 2023 Pre-Funded Warrants, the
“2023 Warrants”) to purchase Common Shares exercisable for an aggregate of
2,536,391 Common Shares. Under the terms of the 2023 Purchase Agreement, for
each Common Share and each 2023 Pre-Funded Warrant issued in the 2023 Private
Placement, an accompanying five-eighths (0.625) of a 2023 Common Warrant was
issued to the purchaser thereof. Each whole 2023 Common Warrant is exercisable
for one Common Share at an exercise price of $3.003 per Common Share, is
immediately exercisable